ask why
Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

The papers that matter: 2 February to 8 February 2026

The 10 most important of the 116 papers published that week and summarised on Y, ranked by what verified readers said would change practice, then by strength of design and size. Secondary analyses come last.
Cardiology · Lancet · 2026-02-05

Meta-analysis of individual data from 19 double-blind trials (123,940 participants) of statin vs placebo: besides known muscle and diabetes effects, only 4 of 66 label-listed adverse outcomes were excess, eg abnormal liver transaminases 0.30% vs 0.22% per year (RR 1.41).

Meta-analysisn = 123,940
Cholesterol Treatment Trialists' (CTT) Collaboration. Electronic address: [email protected] et al. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials

Previous weekNext weekAll weeks

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.